Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lannett Confident Of $1bn In Sales By 2025

Lantus And Advair Among Key Projects

Executive Summary

US-centric generics player Lannett has an ambitious sales and profitability goals for the next five years, driven by several rewarding pipeline opportunities and a leaner cost base. CEO Tim Crew told investors of Lannett’s plans as he presented year-end financial results

You may also be interested in...



Padagis Launches First-To-Market Zomig Nasal Spray Ahead Of Lannett

Less than six months into life as an independent company, former Perrigo Rx unit Padagis has realized its second generic launch, with the first-to-market entry of generic Zomig (zolmitriptan) nasal spray.

FDA Hands Lannett Goal Date On Generic Advair

Lannett continues to eye the potential launch of its partnered Advair generic next year, after the lucrative respiratory asset was accepted for filing by the FDA.

Lannett Adds NovoLog Biosimilar As It Writes Off $198m Of Value

With ambitions of $1bn of sales by 2025, Lannett is looking to bolster its top-line further by expanding its co-development pact with China’s HEC Group for insulin biosimilar products. Management discussed the goal as Lannett presented financial results, which included a significant pre-tax loss.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150207

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel